[go: up one dir, main page]

NO924502L - Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser - Google Patents

Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Info

Publication number
NO924502L
NO924502L NO92924502A NO924502A NO924502L NO 924502 L NO924502 L NO 924502L NO 92924502 A NO92924502 A NO 92924502A NO 924502 A NO924502 A NO 924502A NO 924502 L NO924502 L NO 924502L
Authority
NO
Norway
Prior art keywords
piperazine
carboxamids
treatment
substance abuse
new use
Prior art date
Application number
NO92924502A
Other languages
English (en)
Other versions
NO301311B1 (no
NO924502D0 (no
Inventor
Anders Bjoerk
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO924502D0 publication Critical patent/NO924502D0/no
Publication of NO924502L publication Critical patent/NO924502L/no
Publication of NO301311B1 publication Critical patent/NO301311B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO924502A 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser NO301311B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use
PCT/SE1992/000182 WO1992016211A1 (en) 1991-03-22 1992-03-23 New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (3)

Publication Number Publication Date
NO924502D0 NO924502D0 (no) 1992-11-23
NO924502L true NO924502L (no) 1992-11-23
NO301311B1 NO301311B1 (no) 1997-10-13

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924502A NO301311B1 (no) 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Country Status (24)

Country Link
US (2) US5434156A (no)
EP (1) EP0538422B1 (no)
JP (1) JP3221611B2 (no)
KR (1) KR100196674B1 (no)
AT (1) ATE199057T1 (no)
AU (1) AU653797B2 (no)
BG (1) BG61829B1 (no)
BR (1) BR9204969A (no)
CA (1) CA2083505C (no)
CZ (1) CZ282222B6 (no)
DE (1) DE69231680T2 (no)
DK (1) DK0538422T3 (no)
EE (1) EE02973B1 (no)
ES (1) ES2154261T3 (no)
GR (1) GR3035805T3 (no)
HU (2) HU9203632D0 (no)
IE (1) IE920920A1 (no)
NO (1) NO301311B1 (no)
PT (1) PT100279B (no)
RO (1) RO109702B1 (no)
RU (1) RU2095062C1 (no)
SE (1) SE9100860D0 (no)
SK (1) SK279237B6 (no)
WO (1) WO1992016211A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
CN1486205A (zh) * 2001-01-17 2004-03-31 氟马西尼在用于酒依赖治疗药物制备中的应用
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
WO2003066589A1 (en) 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2021006B1 (en) * 2006-05-09 2015-08-12 Sprout Pharmaceuticals, Inc. Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
AR062321A1 (es) * 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
DE69231680D1 (de) 2001-03-15
AU653797B2 (en) 1994-10-13
ATE199057T1 (de) 2001-02-15
US5618817A (en) 1997-04-08
AU1428092A (en) 1992-10-21
DK0538422T3 (da) 2001-05-07
KR100196674B1 (ko) 1999-06-15
HU9203632D0 (en) 1993-03-29
ES2154261T3 (es) 2001-04-01
EP0538422B1 (en) 2001-02-07
NO301311B1 (no) 1997-10-13
BG97108A (bg) 1994-03-24
EP0538422A1 (en) 1993-04-28
JP3221611B2 (ja) 2001-10-22
CA2083505C (en) 2003-06-10
CA2083505A1 (en) 1992-09-23
IE920920A1 (en) 1992-09-23
PT100279B (pt) 1999-06-30
CZ344992A3 (en) 1994-02-16
JPH05507731A (ja) 1993-11-04
BR9204969A (pt) 1993-07-27
RO109702B1 (ro) 1995-05-30
BG61829B1 (bg) 1998-07-31
NO924502D0 (no) 1992-11-23
RU2095062C1 (ru) 1997-11-10
SK279237B6 (sk) 1998-08-05
DE69231680T2 (de) 2001-06-07
HU217833B (hu) 2000-04-28
KR930700108A (ko) 1993-03-13
SK344992A3 (en) 1995-11-08
PT100279A (pt) 1993-07-30
WO1992016211A1 (en) 1992-10-01
HUT64696A (en) 1994-02-28
SE9100860D0 (sv) 1991-03-22
CZ282222B6 (cs) 1997-06-11
US5434156A (en) 1995-07-18
GR3035805T3 (en) 2001-07-31
EE02973B1 (et) 1997-04-15

Similar Documents

Publication Publication Date Title
NO924502D0 (no) Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
ATE74271T1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
NO20010627L (no) Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
NO982463L (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
JPS55113721A (en) Immunity regulator
RU94044455A (ru) Средство для усиления функции макрофага и лечения человека с ослабленным иммунитетом
KR880012231A (ko) 스테로이드의 용도